UnitedHealth Group (NYSE:UNH | UNH Price Prediction) stock is up 9% today, rising from $323.48 to $351.40, after the company delivered a Q1 2026 earnings report that beat expectations and raised its full-year outlook. The move is lifting the broader managed care sector, with Humana (NYSE:HUM) stock gaining 5%, climbing from $210.34 to $219.91 in sympathy.
The catalyst here is purely operational. Unlike the Medicare Advantage rate decision earlier this month that sent both stocks sharply higher on regulatory relief, today’s rally is about execution. UnitedHealth posted results that showed improving cost discipline and a forward outlook strong enough to lift guidance, signaling that the company’s Medicare Advantage economics may be stabilizing.
UnitedHealth’s Earnings Beat Drives the Rally
UnitedHealth reported adjusted EPS of $7.23 against an estimate of $6.61, a beat of 9%. Revenue came in at $111.72 billion versus estimates of $109.66 billion, growing 2% year over year.
The headline that matters most to the sector is the medical cost ratio. UnitedHealth’s MCR improved 90 basis points to 83.9%, signaling that cost trends are moving in the right direction after a brutal stretch. The UnitedHealthcare segment posted operating earnings of $5.69 billion with an operating margin of 6.6%, up 40 basis points.
On the cash side, the company generated $8.91 billion in operating cash flow, or 1.4x net income. Management also committed to at least $2.0 billion in share buybacks by the end of Q2 2026. UnitedHealth CEO Stephen Hemsley said the company is “continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity.”
Moreover, UnitedHealth raised its full-year 2026 adjusted EPS outlook to greater than $18.25 per share, giving investors a concrete forward signal that management sees the cost improvement holding.
Humana Gets a Lift from Sector Optimism
Humana doesn’t report Q1 2026 results until April 29, but it doesn’t need to. When the largest managed care company in the country shows improving Medicare Advantage cost trends, the sector re-prices. That’s what’s happening today.
Humana stock has been under significant pressure. Its one-year performance sits at -11%, and Humana’s full-year 2026 guidance reflected a steep step-down in profitability as it works through MA repricing and membership recovery. Today’s UnitedHealth results offer early evidence that the repricing effort across the sector may be gaining traction.
Prediction market traders on Polymarket are assigning a 53% probability that Humana beats its upcoming Q1 2026 earnings. That’s a coin flip, but the social sentiment score of 72 suggests retail investors are leaning more optimistic than that headline number implies.
The Turnaround Context: Beaten Down, Now Building
Both stocks have endured a rough year. UNH is down 17% over the past year and HUM is down 11%, with elevated medical costs, Medicare Advantage headwinds, and regulatory uncertainty all contributing to the selloff. That backdrop makes today’s earnings-driven rally feel different from a simple bounce.
The core bear case for both stocks over the past year has centered on Medicare Advantage economics. Rising utilization, unfavorable Star Ratings affecting bonus payments, and aggressive repricing needs all weighed on sentiment. UnitedHealth’s improved MCR is the clearest signal yet that the repricing is working.
It’s worth noting that UnitedHealth did lose 965,000 Medicare Advantage members in Q1 2026, along with 220,000 Medicaid members. The market is clearly willing to accept membership losses in exchange for better margins. That tradeoff is exactly what managed care investors have been waiting to see.
What to Watch Next
Humana’s Q1 2026 earnings on April 29 are the next major test for this rally. If Humana shows a similar improvement in its benefit ratio, the managed care comeback narrative gets a second leg. If it disappoints, today’s sympathy gains could give back ground quickly.
Watch for whether UnitedHealth stock holds above $350 into the close and whether analyst price target upgrades follow. 22 analysts currently rate UNH a Buy against just 2 Sells, so the setup for upward revisions in UnitedHealth and, by extension, for Humana are in play.
Top Gaining Stocks
Top Losing Stocks